



HHS Public Access

Author manuscript

Cancer Cell. Author manuscript; available in PMC 2019 October 08.

Published in final edited form as:

Cancer Cell. 2018 October 08; 34(4): 691. doi:10.1016/j.ccell.2018.09.007.

Non-conventional Inhibitory CD4⁺Foxp3⁺PD-1^{hi} T Cells as a Biomarker of Immune Checkpoint Blockade Activity

Roberta Zappasodi, Sadna Budhu, Matthew D. Hellmann, Michael A. Postow, Yasin Senbabaoglu, Sasikanth Manne, Billel Gasmi, Cailian Liu, Hong Zhong, Yanyun Li, Alexander C. Huang, Daniel Hirschhorn-Cymerman, Katherine S. Panageas, E. John Wherry, Taha Merghoub*, Jedd D. Wolchok*

In the originally published version of this article, the Declaration of Interests section only contained a patent related to this work. Although the below additional disclosures are not directly relevant to the published work, the authors put them forward in the spirit of full transparency. The updated Declaration of Interests disclosure, including a list of author interactions with industry, relevant or not relevant to the study, is reported here and in the online version of the paper. The authors apologize for any inconvenience.

DECLARATION OF INTERESTS

R.Z., T.M., and J.D.W. are inventors on a patent application related to this work, filed by Memorial Sloan Kettering Cancer Center (MSKCC). J.D.W. is a paid consultant to Advaxis, Bristol-Myers Squibb, Merck, Medimmune, Celgene, and Genentech and receives research funding from Bristol-Myers Squibb, Merck, Genentech, and Medimmune and honoraria from Ono Pharmaceuticals. J.D.W. is a co-founder and paid consultant and reports stock option ownership in Potenza Therapeutics, Tizona Therapeutics, and Imvaq. J.D.W. is a paid consultant and reports stock option ownership in Beigene and Apricity. J.D.W. is a paid consultant to Surface Oncology, Polaris, Polynoma, Array, Ascentage, Puretech, Chugai, FStar, Amgen, Sellas Life Sciences, Seramatrix, Neon, Eli Lilly, Psioxus, Syndax, Recepta, Amgen, and Puretech and reports stock option ownership in Adaptive Biotech. T.M. is a co-founder of Imvaq. M.D.H. receives research funding from Bristol-Myers Squibb and is a paid consultant to Merck, Bristol-Myers Squibb, AztraZeneca, Genentech/Roche, Janssen, Nektar, Syndax, Mirati, and Shattuck Labs. M.A.P. has received honoraria from Bristol-Myers Squibb and Merck. He has been a paid consultant to Amgen, Merck, Novartis, Bristol-Myers Squibb, Incyte, Array BioPharma, NewLink Genetics, and Aduro Biotech. His institution receives research support from Bristol-Myers Squibb, Novartis, Array BioPharma, RGenix, and Infinity.

*Correspondence: merghout@mskcc.org (T.M.), wolchokj@mskcc.org (J.D.W.).